Predictive Biomarkers and Targeted Therapies in Gynecological Cancers

  • Louise De Brot
  • Fernando Augusto SoaresEmail author


Gynecological cancers are a very important group of diseases, with a persistently dismal prognosis despite the significant growth in the understanding of the molecular biology of neoplasia. Targeted therapy is currently a reality only for ovarian and cervical cancers, where angiogenesis plays a very important role, sufficient for good clinical results with the adoption of antiangiogenic therapy, especially in the combination with conventional chemotherapy. In the other fields, there is still a scarcity of predictive biomarkers for therapy, despite great understanding of biological and pathological pathways linked to development and evolution of neoplasia. This chapter focuses on the current understanding and the possible next steps on predictive biomarkers for ovarian, cervical, vulvar, vaginal, and endometrial cancers, including the next frontiers to be broken in therapeutics.


Biomarkers Molecular oncology Gynecological cancer Predictive Targeted therapy Immunotherapy Pathways 


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.CrossRefPubMedGoogle Scholar
  3. 3.
    Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10(4):211–24.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.CrossRefPubMedGoogle Scholar
  5. 5.
    Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014;32(25):2687–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Arrossi S, Temin S, Garland S, Eckert LON, Bhatla N, Castellsagué X, et al. Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. J Glob Oncol. 2017;3(5):611–34.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bailey HH, Chuang LT, NC DP, Eng C, Foxhall LE, Merrill JK, et al. American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention. J Clin Oncol. 2016;34(15):1803–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–108.CrossRefGoogle Scholar
  9. 9.
    Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.CrossRefGoogle Scholar
  10. 10.
    Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41.CrossRefGoogle Scholar
  11. 11.
    Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134(2):385–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Gadducci A, Fabrini MG, Lanfredini N, Sergiampietri C. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. Crit Rev Oncol Hematol. 2015;93(3):211–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Tyring SK. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obst Gynecol. 2003;189(3 Suppl):S17–23.CrossRefGoogle Scholar
  14. 14.
    Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark. 2010;8(0):231–51.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Tarala DN. Biomarkers for cancers in women: present status and future perspectives. Curr Women Health Rev. 2012;8(4):297–311.Google Scholar
  16. 16.
    Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403.CrossRefPubMedGoogle Scholar
  17. 17.
    Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol. 2009;6(6):315–26.CrossRefPubMedGoogle Scholar
  18. 18.
    Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6(9):507–18.CrossRefPubMedGoogle Scholar
  19. 19.
    Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569–79.CrossRefPubMedGoogle Scholar
  20. 20.
    Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol. 2017;145(2):393–406.CrossRefPubMedGoogle Scholar
  21. 21.
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.CrossRefPubMedGoogle Scholar
  23. 23.
    Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Holthausen JT, Wyman C, Kanaar R. Regulation of DNA strand exchange in homologous recombination. DNA Repair. 2010;9(12):1264–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Renkawitz J, Lademann CA, Jentsch S. Mechanisms and principles of homology search during recombination. Nat Rev Mol Cell Biol. 2014;15(6):369–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Muggia F, Safra T. ‘BRCAness’ and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014;34(2):551–6.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.CrossRefGoogle Scholar
  29. 29.
    Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.CrossRefGoogle Scholar
  30. 30.
    Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Eng J Med. 2016;375(22):2154–64.CrossRefGoogle Scholar
  31. 31.
    Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33(12):1397–406.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Mullard A. PARP inhibitors plough on. Nat Rev Drug Discov. 2017;16(4):229.PubMedGoogle Scholar
  34. 34.
    Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors – moving to the adjuvant setting. Nat Rev Clin Oncol. 2015;12(1):27–41.CrossRefPubMedGoogle Scholar
  35. 35.
    Heong V, Ngoi N, Tan DSP. Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol. 2017;28(2):e20.CrossRefPubMedGoogle Scholar
  36. 36.
    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–22.CrossRefPubMedGoogle Scholar
  38. 38.
    Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028. J Clin Oncol. 2017;35(15_suppl):5513.CrossRefGoogle Scholar
  39. 39.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Tewari KS, Sill MW, Long HJI, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–84.CrossRefGoogle Scholar
  42. 42.
    Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–41.CrossRefPubMedGoogle Scholar
  43. 43.
    Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther. 2018;5(2).
  44. 44.
    Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol. 2011;29(16):2259–65.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41.CrossRefPubMedGoogle Scholar
  46. 46.
    Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98.CrossRefPubMedGoogle Scholar
  47. 47.
    Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Anatomic PathologyA.C. Camargo Cancer CenterSão PauloBrazil
  2. 2.Department of PathologyRede D’Or Hospital NetworkSão PauloBrazil

Personalised recommendations